Logo

Cepheid Takes PCR License from Roche for In Vitro Diagnostics

Jun 24, 2004

NEW YORK, June 24 (GenomeWeb News) - Cepheid has licensed several PCR-related patents from Roche for in vitro diagnostic products, the Sunnyvale, Calif.-based company said today.

 

The non-exclusive license comprises Roche patents covering the PCR process, reverse transcription-based methods, nucleic acid quantification methods, real-time PCR detection, and methods for the detection of viral and cancer targets.

 

Cepheid is permitted to make, use, and sell products based on these technologies for in vitro human diagnostics, except for human identify testing and pathogen detection for blood bank screening and plasma fractionation. Cepheid will pay Roche a licensing fee and ongoing royalties on sales of relevant products.

 

Yesterday, Cepheid said it has expanded its license to Applera's PCR patents to include real-time PCR.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.